obesity

R&D

Concept of AI overview of patient in clinical trial

How AI simulation could help de-risk obesity and cardiometab...

AI life sciences models allow researchers to explore different patient populations, protocols, and development strategies before a study starts.

News

Under pressure, Novo lays out blockbuster launch plans

Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.

News

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

News

UK MHRA authorises orforglipron private prescription

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

R&D

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

How AI simulation could help de-risk obesity and cardiometab...

Under pressure, Novo lays out blockbuster launch plans

Novo Nordisk's IL-6 drug flunks two more heart trials

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

UK MHRA authorises orforglipron private prescription

GLP-1 RAs in CKM management: A Q&A with CORXEL

Click claims FDA okay for first-in-class schizophrenia DTx

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks